Differences in daytime and nocturnal IOP identified

Article

The identified nocturnal differences in intraocular pressure (IOP) include reductions in aqueous flow, outflow facility and uveoscleral outflow, according to a study published in the Archives of Ophthalmology.

The identified nocturnal differences in intraocular pressure (IOP) include reductions in aqueous flow, outflow facility and uveoscleral outflow, according to a study published in the Archives of Ophthalmology.

Dr Hong Liu et al., Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA, studied 30 healthy participants. The measurements included IOP by pneumatonometry, aqueous flow by fluorophotometry, outflow facility by fluorophotometry and tonography, uveoscleral outflow by mathematical calculation, central cornea thickness by pachymetry, and blood pressure by sphygmomanometry. Each subject underwent 1 daytime visit and 1 nocturnal visit for the recording of aqueous humor dynamics.

The findings demonstrated that seated IOP was reduced by 16% when compared during the day and night. Nocturnal supine IOP increased by 17%. During the night, aqueous flow was reduced by 49% and fluorophotometric outflow facility was reduced by 45%. Uveoscleral outflow was lowered only when using tonographic outflow facility. All other measurements remained the same.

The results also suggested that nocturnal changes in IOP are influenced by the posture of the individual.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.